Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma
Phase of Trial: Phase II
Latest Information Update: 01 May 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Leukaemia; Lymphoma; Lymphoproliferative disorders
- Focus Therapeutic Use
- 07 Jun 2016 Results of two completed phase II trials (NCT00436618 and NCT00918333) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 15 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 02 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.